昂利康(002940.SZ):NHKC-1是公司未來抗高血壓藥物管線上新的梯隊產品
格隆匯7月12日丨昂利康(002940.SZ)近期在接待機構投資者調研時表示,NHKC-1是公司未來抗高血壓藥物管線上新的梯隊產品,目前該產品已取得藥物臨牀試驗批准通知書。公司與陽光諾和共同投資開發該項目,雙方各佔權益的50%,公司需向陽光諾和按照研究進度里程碑付款支付研發費用總金額7,500萬元,該項目獲准上市後的生產製造、全國市場銷售由昂利康負責,項目的MAH上市許可持有人由陽光諾持有並完成後續註冊申報工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.